Bennett C. Frank, Executive Vice President and Chief Scientific Officer, has demonstrated a clear pattern of selling activity in Ionis Pharmaceuticals (IONS) shares, as evidenced by SEC Form 4 filings. Over the course of 42 transactions, Frank has sold shares totaling $19.55 million, significantly outweighing purchases valued at $9.88 million. Notably, all 12 of his most recent trades, spanning from January 2026 to March 2026, were sales, with transactions ranging from $12,754.16 to $5.66 million. The largest single sale occurred on March 3, 2026, when Frank disposed of shares worth $5.66 million, followed by another significant sale of $4.04 million on February 2, 2026. These transactions were complemented by smaller sales, such as $488,140.74 on January 30, 2026, and $674,621.55 on January 16, 2026. Additionally, Frank’s activity includes multiple transactions coded as "M" (derivative securities) and "J" (other acquisitions), though these primarily involve smaller values or non-monetary events. The consistent selling trend, particularly in early 2026, suggests a deliberate reduction in Frank’s holdings in Ionis Pharmaceuticals. This activity aligns with a broader pattern of divestment, as Frank has not engaged in any recent purchases of the company’s shares.
AI-assisted summary